Skip to main content

Table 3 Demographics and health characteristics of Phase 2 clinical trial sample

From: Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept

Characteristic

Active recurrence (A-RP)

Not symptomatic, Corticosteroid-dependent (CSD-RP)

N = 16

N = 9

Age (years) (Mean ± SD [range])

39.8 ± 10.52 (26–58)

48.2 ± 8.56 (36–62)

Gender (% female [n])

75.0% (n = 12)

33.3% (n = 3)

Race (% white [n])

81.3% (n = 13)

100% (n = 9)

BMI (kg/m2) (Mean ± SD [range])

31.99 ± 7.51 (23.4–52.7)

28.97 ± 4.68 (22.5–34.3)

Duration of disease (years) (Mean ± SD [range])

2.6 ± 2.13 (0.2–7.9)

1.4 ± 0.97 (0.6–3.4)

Number of prior recurrences (median, [range])

2 (1–8)

3 (2–5)

Baseline NRS Pain Rating 0–10 (Mean ± SD [range])

4.6 ± 1.82 (2–8)

1.4 ± 1.51 (0–5)

Baseline CRP values (mg/dL) (Mean ± SD [range])

3.8 ± 5.30 (0.09–19.84)

0.19 ± 0.11 (0.05–0.36)

Concomitant medications at baseline

Aspirin (n [%])

0 (0%)

2 (22.2%)

NSAID (n [%])

7 (43.8%)

5 (55.6%)

Colchicine (n [%])

12 (75.0%)

8 (88.9%)

CS (n [%])

6 (37.5%)a

9 (100.0%)b

  1. BMI = body mass index; CRP = c-reactive protein; CS = corticosteroids; EP = extension period; NRS = numeric rating scale; NSAID = nonsteroidal anti-inflammatory drug; SD = standard deviation
  2. a4/6 (66.7%) discontinued CS and 1/6 (16.7%) tapered CS by end of EP; 1/6 (16.7%) did not enter EP
  3. b7/9 (77.8%) discontinued CS and 1/9 (11.1%) tapered CS by end of EP; 1/9 (11.1%) did not enter EP